Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | PLAT | P00750 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 2/20 | 0.38 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | TLR4 | O00206 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5599223 | 0.89 | LMNA (0.41) | LMNAPLGPLATANPEPENPEP | |
| SCHEMBL5599221 | 0.89 | LMNA (0.41) | LMNAPLGPLATANPEPENPEP | |
| SCHEMBL6459367 | 0.89 | LMNA (0.41) | LMNAPLGPLATANPEPENPEP | |
| SCHEMBL10800959 | 0.88 | POLB (0.47) | LMNAPLGPLATANPEPENPEP | |
| SCHEMBL1875388 | 0.88 | POLB (0.47) | LMNAPLGPLATANPEPENPEP | |
| SCHEMBL849696 | 0.88 | ANPEP (0.50) | LMNAPLGPLATANPEPALDH1A1 | |
| SCHEMBL223128 | 0.87 | LMNA (0.56) | LMNAPLGPLATANPEPENPEP | |
| SCHEMBL3512672 | 0.87 | LMNA (0.56) | LMNAPLGPLATANPEPENPEP | |
| SCHEMBL223127 | 0.87 | LMNA (0.56) | LMNAPLGPLATANPEPENPEP | |
| Hydrochloric Acid SCHEMBL7876220 | 0.85 | LMNA (0.54) | LMNAPLGPLATANPEPENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362073-B2 | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2013-01-29 | — | — | US | disclosed |
| US-20110152290-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | disclosed |
| EP-0450066-B1 | CARBOSTYRIL DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 1996-09-11 | — | — | EP | disclosed |
| US-5401740-A | FOR INHIBITING PLATELET AGGREGATION | OTSUKA PHARMACEUTICAL CO. (JP) | 1995-03-28 | — | — | US | disclosed |
| US-5227381-A | Anticoagulant | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-13 | — | — | US | disclosed |
| EP-0450066-A1 | CARBOSTYRIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-10-09 | — | — | EP | disclosed |
| US-4945177-A | Antimicrobially active nitriles and the production thereof | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1990-07-31 | — | — | US | disclosed |
| EP-0220220-B1 | PROCESS OF PREPARING 2,2-DIBROMO-3-OXONITRILES | Henkel Kommanditgesellschaft auf Aktien (DE) | 1990-05-23 | — | — | EP | disclosed |
| EP-0220250-A1 | UTILIZATION OF NITRILES AS ANTIMICROBIAL AGENTS | Henkel Kommanditgesellschaft auf Aktien (DE) | 1987-05-06 | — | — | EP | disclosed |
| EP-0220220-A1 | Process of preparing 2,2-dibromo-3-oxonitriles. | HENKEL KGAA (DE) | 1987-05-06 | — | — | EP | disclosed |
| WO-1986006369-A1 | ANTI-MICROBIAL NITRILE AND ITS PRODUCTION | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1986-11-06 | — | — | WO | disclosed |
| WO-1986006254-A1 | UTILIZATION OF NITRILES AS ANTIMICROBIAL AGENTS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1986-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152290-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | LMNA 1259/4885PLG 96/4885PLAT 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.